Funding Measure

GARDP

The Global Antibiotic Research & Development Partnership (GARDP) is a joint initiative of Drugs for Neglected Diseases initiative (DNDi) and the World Health Organization (WHO). GARDP is a non-profit research and development initiative that develops new therapies for bacterial infections. The focus is on infections in which antimicrobial resistance (AMR) is already present or has emerged, or where adequate treatment is currently unavailable. It addresses, in particular, gaps in public health and takes measures for sustainable, equitable and affordable access into account. GARDP has four programs that develop treatments for different areas.

Subprojects

Finished

Antimicrobial Memory Recovery & Exploratory Programme

Reference number: 01KA1833
Total Funding Amount: 10.800.000 EUR
Funding Period: 2018 - 2023
Project leader: Dr. Francois Franceschi
Address: Global Antibiotic Research & Development Partnership (GARDP)
15 Chemin Louis-Dunant
1202 Genf, Schweiz

Antimicrobial Memory Recovery & Exploratory Programme

The Antimicrobial Memory Recovery & Exploratory Programme aims to recover the knowledge, data, and assets of forgotten, abandoned, or withdrawn antibiotics while the search for new classes is pursued, and a new generation of researchers in antibiotic R&D is championed.

Finished

Paediatric Antibiotics Programme

Reference number: 01KA1832
Total Funding Amount: 10.000.000 EUR
Funding Period: 2018 - 2023
Project leader: Dr. Seamus O´Brien
Address: Global Antibiotic Research & Development Partnership (GARDP)
15 Chemin Louis-Dunant
1202 Genf, Schweiz

Paediatric Antibiotics Programme

Antibiotics for children have often not been developed for the needs of children. GARDP’s paediatric antibiotic programme aims to expedite the development of new, improved and adapted antibiotics to treat serious bacterial infections in children of-all-ages. Approaches include, for example, dose improvement the, change of the duration of treatment and / or the formulation of the medication.

Finished

Sexually Transmitted Infections Programme

Reference number: 01KA1831
Total Funding Amount: 14.700.000 EUR
Funding Period: 2018 - 2023
Project leader: Dr. Emilie Alirol
Address: Global Antibiotic Research & Development Partnership (GARDP)
15 Chemin Louis-Dunant
1202 Genf, Schweiz

Sexually Transmitted Infections Programme

A significant sexually transmitted infection (STI), Neisseria gonorrhoeae is threatening to soon become untreatable due to its resistance to all available classes of antimicrobials. This programme is designed to accelerate the entry of new antibiotics for the treatment of gonorrhea and to investigate the use of novel drug combinations.

Finished

Neonatal Sepsis Programme

Reference number: 01KA1830
Total Funding Amount: 14.500.000 EUR
Funding Period: 2018 - 2023
Project leader: Dr. Sally Ellis
Address: Global Antibiotic Research & Development Partnership (GARDP)
15 Chemin Louis-Dunant
1202 Genf, Schweiz

Neonatal Sepsis Programme

The GARDP neonatal sepsis programme aims to provide an evidence base for the use of antibiotics, both old and new, in neonates with serious bacterial infections (SBIs), as the currently available standard of care in many countries is increasingly becoming less effective due to antimicrobial resistance. One of the long-term goals is the clinical development of formulations that are especially adapted for use in neonates.